CLVS - クロビス・オンコロジ― (Clovis Oncology Inc.) クロビス・オンコロジ―

 CLVSのチャート


 CLVSの企業情報

symbol CLVS
会社名 Clovis Oncology Inc (クロビス・オンコロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クロービス・オンコロジー(Clovis Oncology Inc.)は米国、ヨーロッパ及び他の国際市場における抗癌剤の取得・開発・商品化に従事するバイオ医薬品会社である。同社の製品候補にはロシリチニブ、ルブラカ(ルカパリブ)及びルシチニブを含む。ルカパリブは損傷デオキシリボ核酸乳癌(DNA)の修復関連ヒト遺伝子の乳がん(BRCA)突然変異患者の治療向け単剤療法として承認されたPARP1、PARP2及びPARP3の経口小分子ポリアデノシン二リン酸(ADP)・リボースポリメラーゼ(PARP)阻害剤である。ルシチニブは、血管内皮増殖因子受容体(VEGFR)1-3、血小板由来増殖因子受容体(PDGFR)αとβ及び線維芽細胞増殖因子受容体(FGFR)1-3のチロシンキナーゼ活性の経口阻害剤である。ロシリチニブは表皮成長因子受容体(EGFR)の経口突然変異選択的阻害剤である。   クロビス・オンコロジ―は米国のバイオ医薬品会社。抗がん剤の買収、開発、商業化を手掛ける。非小細胞肺がん治療用に経口の選択的・非可逆的EGFR阻害剤CO-186を、また、卵巣がんおよびすい臓がん治療用にポリ(ADP-リボ―ス)ポリメラ―ゼ阻害剤ルカパリブの臨床開発を実施している。   
本社所在地 5500 Flatiron Parkway Suite 100 Boulder CO 80301 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-625-5000
設立年月日 39904
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 360人
url www.clovisoncology.com
nasdaq_url https://www.nasdaq.com/symbol/clvs
adr_tso
EBITDA EBITDA(百万ドル) -268.68600
終値(lastsale) 30.34
時価総額(marketcap) 1597388590.94
時価総額 時価総額(百万ドル) 1531.05
売上高 売上高(百万ドル) 76.12600
企業価値(EV) 企業価値(EV)(百万ドル) 1423.143
当期純利益 当期純利益(百万ドル) -129.23100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Clovis Oncology Inc revenues increased 95% to $42.3M. Net loss decreased 24% to $178.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Legal settlement loss decrease of 93% to $8M (expense) Other income increase from $948K to $2.9M (income).

 CLVSのテクニカル分析


 CLVSのニュース

   50 Biggest Movers From Friday  2021/03/22 07:27:06 Benzinga
Gainers Clovis Oncology, Inc. (NASDAQ: CLVS ) shares climbed 47.7% to … Full story available on Benzinga.com
   Clovis Oncology stock soars 40% in early trading on positive Phase III data  2021/03/19 23:04:06 Daily Camera
Clovis Oncology Inc. (Nasdaq: CLVS) said the top-line data of its Phase III trial showed that its flagship product Rubraca fulfilled the study’s top objective in ovarian cancer patients, sending share prices flying Friday morning.
   Clovis Oncology Stock Rallies: Technical Levels To Watch  2021/03/19 17:48:34 Benzinga
Clovis Oncology Inc. (NASDAQ: CLVS ) shares are gaining ground in Friday’s session. The jump in the shares comes after a company announcement stating that Rubraca significantly improves progression-free survival versus chemotherapy in patients with later-line ovarian cancer associated with a BRCA mutation. The stock is trading with a market cap of $585 million and a public float of 86.4 million shares. The stock was trading 53.7% higher at $2.86 at last check. Clovis Short-Term Chart Analysis: The 5-minute chart above shows the stock ran to $7 in Friday’s premarket session. The stock then consolidated and broke over … Full story available on Benzinga.com
   Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday  2021/03/19 16:43:54 Benzinga
Clovis Oncology, Inc. (NASDAQ: Full story available on Benzinga.com
   Clovis Oncology Inc $CLVS: Cash per share is $2, and the stock price is $5.32!  2021/03/19 13:29:59 StockMarketRevolution
Business Profile Headquartered in Boulder, COLORADO, Clovis Oncology Inc (CLVS) trades at $5.32 a piece in the Nasdaq Global Select:
   Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting  2021/02/11 13:00:00 Business Wire
Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO GU 2021 Virtual Meeting
   PARP Inhibitor Market Covid19 Impact - AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc.  2021/02/08 12:45:50 OpenPR
Coherent Market Insights announced that it’s published an exclusive report namely Global PARP Inhibitor Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The
   $CLVS #CLOVISONCOLOGY - Stocks Rebounded on Stimulus Hope  2021/02/03 14:26:54 CentralCharts
STATE OF THE MARKETS Stocks rebounded on stimulus hope. US equities rebounded on optimism over new stimulus spending to revive the world’s largest economy after being plagued by the corona pandemic. The US senate took steps to allow Democrats to pass Biden’s package without Republican support, which boosted optimism and saw some return of Treasury demands around $95 billions. The 10Y benchmark yielded higher to close around 1.10% compared to 1.08% on Monday. Crude continued its upward trajectory, closed above $54.75/bl as reports showed that OPEC+ countries are curbing output as per voluntary commitment, which helped support price as producers are trying cope with the flagging demand. Markets optimism sent gold as low as $1,829.46/oz before settled around $1,837.35/oz as markets closed. In the FX space, the Greenback took the helm of demand in the medium and long term accounts as it retreated in the short-term. The higher interest bearing Kiwi and Loonie, returned to demand, while Aussie remain suppressed despite the RBA decision to keep rate unchanged.
   Global Ovarian Cancer Drug Market Trends,Outlook,Size,Share,Covid-19 Impact Analysis By Clovis Oncology, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc  2021/02/02 11:34:47 OpenPR
Global Ovarian Cancer Drug market report gives essential information, objective insights regarding international market trends and leads, competitor analysis, and much more. All the teams involved in generating this market research report including consultants, market researchers, and data providers work
   Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020  2021/01/11 13:00:00 Business Wire
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended Dece
   PARP Inhibitor Market Covid19 Impact - AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc.  2021/02/08 12:45:50 OpenPR
Coherent Market Insights announced that it’s published an exclusive report namely Global PARP Inhibitor Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The
   $CLVS #CLOVISONCOLOGY - Stocks Rebounded on Stimulus Hope  2021/02/03 14:26:54 CentralCharts
STATE OF THE MARKETS Stocks rebounded on stimulus hope. US equities rebounded on optimism over new stimulus spending to revive the world’s largest economy after being plagued by the corona pandemic. The US senate took steps to allow Democrats to pass Biden’s package without Republican support, which boosted optimism and saw some return of Treasury demands around $95 billions. The 10Y benchmark yielded higher to close around 1.10% compared to 1.08% on Monday. Crude continued its upward trajectory, closed above $54.75/bl as reports showed that OPEC+ countries are curbing output as per voluntary commitment, which helped support price as producers are trying cope with the flagging demand. Markets optimism sent gold as low as $1,829.46/oz before settled around $1,837.35/oz as markets closed. In the FX space, the Greenback took the helm of demand in the medium and long term accounts as it retreated in the short-term. The higher interest bearing Kiwi and Loonie, returned to demand, while Aussie remain suppressed despite the RBA decision to keep rate unchanged.
   Global Ovarian Cancer Drug Market Trends,Outlook,Size,Share,Covid-19 Impact Analysis By Clovis Oncology, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc  2021/02/02 11:34:47 OpenPR
Global Ovarian Cancer Drug market report gives essential information, objective insights regarding international market trends and leads, competitor analysis, and much more. All the teams involved in generating this market research report including consultants, market researchers, and data providers work
   Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020  2021/01/11 13:00:00 Business Wire
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended Dece
   Global Ovarian Cancer Drug Market Growth Factors And Future Scope To 2026||Top Leaders- AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology  2020/12/29 18:58:18 OpenPR
According to the Ovarian Cancer Drug Market report, the global market is expected to witness a relatively higher growth rate during the forecast period. Analysis and discussion of important industry trends, market size, market share estimates are mentioned in the

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クロビス・オンコロジ― CLVS Clovis Oncology Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)